Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).

Name: Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).
Author: Azim, Hamdy A

Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study). — المؤلف: Azim, Hamdy A — Journal of hepatocellular carcinoma 2018

المؤلف: Azim, Hamdy A
النشر: Journal of hepatocellular carcinoma 2018
الوصف: 109-119 p.